GHRP-6 Peptide Guide: Dosing, Reconstitution & Safety (2026)

GHRP-6 stands for growth hormone releasing peptide-6. It is a small synthetic peptide (six amino acids) that copies part of how the hunger hormone ghrelin works. Instead of adding growth hormone (GH) from outside, it signals your own pituitary gland to release a pulse of GH. It was the first peptide of its kind, described by Cyril Bowers in 1984.

Two honest points up front. First, GHRP-6's standout trait is strong appetite stimulation — the most of any peptide in its family. That can help someone trying to eat more, but it works against most fat-loss or lean-physique goals. Second, the GH rise is real but modest compared with injectable HGH, so results depend heavily on training, sleep, and nutrition. It is most often paired with a GHRH analog (like CJC-1295 / mod GRF 1-29 or sermorelin) because the two together produce a bigger GH pulse than either alone.

Most GHRP-6 dosing discussions come back to two practical ideas: the saturation dose and meal timing. The saturation dose is the point where adding more peptide is unlikely to add much more GH response, and food near the injection window can blunt the pulse. The figures below are educational only, not dosing instructions.

GHRP-6 comes as a freeze-dried (lyophilized) powder, most commonly in a 5 mg vial. You mix it with bacteriostatic water before use. The math below assumes a 5 mg vial with 3 mL bacteriostatic water, which is the max-volume assumption used on this page.

This GHRP-6 dosage chart summarizes the SubQ research schedule from 100 mcg to 300 mcg per injection, with each phase shown by week range, dose, and injection frequency.

In plain terms, GHRP-6 acts like the hunger hormone ghrelin. It binds a receptor in the pituitary and brain and tells the body to release a short burst of its own growth hormone. That burst then raises IGF-1, the downstream signal tied to recovery and tissue growth.

Technically, GHRP-6 is an agonist at the growth hormone secretagogue receptor 1a (GHS-R1a), the same receptor ghrelin uses. This pathway is separate from growth hormone-releasing hormone (GHRH), which is why combining GHRP-6 with a GHRH analog produces a bigger pulse than either alone. The same receptor also drives appetite in the hypothalamus, which explains the strong hunger.

Some groups should not use GHRP-6 without close medical guidance, mainly because growth hormone affects blood sugar and because of its unproven long-term safety.

This list is not complete. A qualified clinician should review your full history, medications, and lab work first.

The most consistent effect is intense hunger, often within minutes of a dose. Other commonly reported effects include water retention or puffiness, tingling or numbness in the hands (a GH-related effect), a brief head-rush or flushing, and tiredness.

At higher doses, GHRP-6 also nudges up cortisol and prolactin, more than newer peptides like ipamorelin do. Because GH affects glucose, blood sugar and insulin sensitivity can shift, which matters most for people with diabetes or prediabetes.

The GH pulse itself happens within minutes of a dose, and appetite often spikes just as fast. But visible body-composition changes are slow and modest. Where they happen, they usually need consistent use over about 8 to 12 weeks alongside training and good nutrition. GHRP-6 is not a substitute for injectable HGH and should not be expected to match it.

One mechanism detail worth knowing: repeated high doses can blunt the response over time (desensitization), which is part of why dosing near the saturation point, not above it, is the common approach. People monitoring effects often track IGF-1 and, if relevant, fasting glucose.

The biology is well documented; the physique claims are not. Here is how the evidence splits.

Bottom line: GHRP-6 reliably does what its name says (it releases GH and drives hunger), but the leap to body-composition results is not well supported by controlled human trials.

Reconstituted peptide is generally used within a few weeks; follow the supplier's stated stability where available.

As of June 2026, GHRP-6 has no FDA-approved use and no approved drug product in major regulated markets. Its close relative GHRP-2 was approved in Japan as a diagnostic agent (pralmorelin), but GHRP-6 itself has no such approval.

Regulatory categories change. Confirm current status before relying on any of the above.

GHRP-6 sits in a crowded field. The quick differences below explain the most-searched comparisons.

If you are researching GHRP-6 for GH support, these are the most useful next reads: Ipamorelin (the cleaner alternative), Sermorelin and CJC-1295 (no DAC) (the GHRH analogs often paired with it), and the CJC-1295 + Ipamorelin GH Pulse stack.